Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials

BACKGROUND: Copanlisib is an intravenously administered pan-class I PI3K inhibitor that has been demonstrated to have appreciable effects in the treatment of patients with lymphoma. The purpose of this meta-analysis was to evaluate the efficacy and safety of copanlisib for treating patients with rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jinjin, Zhou, Hui, Mu, Mingchun, Zhao, Ailin, Cai, Zhaolun, Li, Linfeng, Wang, Mengyao, Niu, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691663/
https://www.ncbi.nlm.nih.gov/pubmed/36439091
http://dx.doi.org/10.3389/fimmu.2022.1034253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691663/
https://www.ncbi.nlm.nih.gov/pubmed/36439091
http://dx.doi.org/10.3389/fimmu.2022.1034253

Ejemplares similares